Pulmonary Multidrug-Resistant Bacterial Infection
Conditions
Interventions
Control group:Sensitive antibiotic anti-infective treatment physical cooling Fluid replacement expectoration asthma relief respiratory support
Experimental Group:Qingfeihuatan Drink Sensitive antibiotic anti-infective treatment physical cooling Fluid replacement expectoration asthma relief respiratory support
Sponsors
Ningxia Hui Autonomous Region Hospital and Research Institute of traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Ages between 18 and 80 gender not limited. 2.Patients with community-acquired or hospital-acquired pneumonia. 3.The etiological culture of qualified specimens identifies the type of infecting pathogen and the drug resistance profile of multidrug-resistant bacteria clearly. 4.Traditional Chinese Medicine (TCM) diagnosis of Qi deficiency with phlegm-heat and blood stasis obstruction syndrome: Main symptoms: Cough shortness of breath or hoarse cough yellow or white phlegm that is dry or sticky fatigue and lack of energy. Secondary symptoms: Chest and rib-side pain red face and body fever thirst with yellow urine dry stools or abdominal bloating. Tongue and pulse: Dark red tongue tortuous sublingual vessels yellow or greasy yellow coating slippery and thin pulse or slippery and thin rapid pulse. Participants who meet the main symptoms one or more secondary symptoms and have one of the tongue and pulse conditions can be diagnosed. 5.Voluntarily participate in this trial provide informed consent and sign a written informed consent form.
Exclusion criteria
Exclusion criteria: 1.Pregnant and breastfeeding women. 2.Acute organ dysfunction involving 3 or more organs. 3.Acute Physiology and Chronic Health Evaluation II (APACHE II) score greater than 20. 4.Allergic to the medication used in this trial. 5.Individuals with severe primary diseases involving the heart liver kidneys and hematopoietic system those in the advanced stages of malignant tumors those with poorly controlled diabetes patients after organ transplantation and patients with mental illness. 6.The investigator deems it inappropriate for the subject to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effective rate;Bacterial clearance rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| White cell count;Procalcitonin;Interleukin-6;D-dimer;Plasma albumin;CPIS score;Pneumonia absorption score;Reduction rate of TCM symptom score;C-reactive protein;Neutrophil count;28-day mortality; | — |
Countries
P.R.China
Contacts
Public ContactLi Yanni
Ningxia Hui Autonomous Region Hospital and Research Institute of traditional Chinese Medicine
Outcome results
None listed